Carlton Hofferkamp & Jenks Wealth Management LLC Sells 700 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Carlton Hofferkamp & Jenks Wealth Management LLC reduced its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 10.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 5,850 shares of the biopharmaceutical company’s stock after selling 700 shares during the quarter. Carlton Hofferkamp & Jenks Wealth Management LLC’s holdings in Gilead Sciences were worth $583,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. HHM Wealth Advisors LLC grew its position in shares of Gilead Sciences by 118.5% in the 4th quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 154 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $28,000. Decker Retirement Planning Inc. bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $29,000. Crews Bank & Trust bought a new stake in shares of Gilead Sciences during the fourth quarter valued at approximately $31,000. Finally, Stephens Consulting LLC boosted its position in shares of Gilead Sciences by 325.0% during the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 260 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the sale, the chief financial officer now owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. The trade was a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders sold 293,356 shares of company stock valued at $29,166,240. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Stock Up 1.5 %

Gilead Sciences stock opened at $115.99 on Tuesday. The stock has a market cap of $144.55 billion, a PE ratio of 313.49, a price-to-earnings-growth ratio of 0.71 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $117.16. The stock has a fifty day moving average of $97.87 and a 200 day moving average of $90.45.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.72%. The ex-dividend date is Friday, March 14th. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. Gilead Sciences’s payout ratio is currently 854.05%.

Analyst Ratings Changes

Several research firms recently weighed in on GILD. Royal Bank of Canada lifted their price target on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. BMO Capital Markets lifted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the company an “outperform” rating in a research note on Wednesday, February 12th. Maxim Group cut Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. UBS Group lifted their price objective on Gilead Sciences from $70.00 to $96.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a “neutral” rating in a research note on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $102.08.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.